leadf
logo-loader
viewProactive Group

Shares of MediciNova may advance after triglycerides treatment results meet goal of clinical study

Company will stop study to accelerate development of treatment

test tubes
The stock gained 13% in pre-market trading

Shares of MediciNova Inc. (NASDAQ:MNOV) may rise after the biopharmaceutical company said its tipelukast treatment aimed at reducing trigylcerides in patients with fibrosis met the goal of the clinical trial.

The stock climbed 13% to US$14.95 in pre-market trading.

“Tipelukast significantly reduced mean serum triglycerides, a primary endpoint, during the study,” the company said in a statement. “Having achieved the most important endpoint of the study, MediciNova has discontinued enrollment and will stop the study in order to accelerate further development” of the treatment, it said.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Ascendant Resources drill program continues looking to expand south zone at...

Ascendant Resources (TSE: AND) President and CEO Chris Buncic joined Steve Darling from Proactive with news the company's drill program continues as the look at the South Zone of the Lagoa Salgada Project in Portugal. Buncic telling Proactive they are expecting to have results from this...

26 minutes ago

2 min read